DIADEMA PARTNERS LP
13F Reported Value
ⓘ$587.7M
incl. option notional
Equity Holdings
ⓘ$242.2M
Option Notional
ⓘ$345.6M
$137.3M puts / $208.2M calls
Holdings
144
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
DIADEMA PARTNERS LP disclosed 144 positions worth $587.7M in its Form 13F-HR for Q1 2026 — $242.2M in common stock plus $345.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $VRTX (VERTEX PHARMACEUTICALS INC / MA) calls, followed by $LQDA and $UTHR. During the quarter the fund opened 74 new positions and exited 76 — including a new stake in $LQDA. The portfolio is most concentrated in Healthcare (91.4% of disclosed assets). All figures are sourced directly from DIADEMA PARTNERS LP’s Form 13F-HR filing with the SEC under CIK 2026172.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 76.6#101
Quality
$41.6M93,100 sh - 37.4#2,056
Quality
$25.0M662,100 sh - 80.1#46
Quality
$23.8M40,200 sh - $21.5M659,200 sh
- $19.0M623,400 sh
- $18.7M222,500 sh
BRIDGEBIO PHARMA INC
—Quality
$18.6M250,000 sh- —
Quality
$17.1M525,181 sh - 80.1
Quality
$16.2M27,303 sh - 28.0
Quality
$13.2M200,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 VERTEX PHARMACEUTICALS INC / MA$VRTXCALL | 76.6#101 | $41.6M | 93,100 |
 Liquidia Corp$LQDACALL | 37.4#2,056 | $25.0M | 662,100 |
 UNITED THERAPEUTICS Corp$UTHRCALL | 80.1#46 | $23.8M | 40,200 |
 Viking Therapeutics, Inc.$VKTXCALL | — | $21.5M | 659,200 |
 CAPRICOR THERAPEUTICS, INC.$CAPRPUT | — | $19.0M | 623,400 |
 Apogee Therapeutics, Inc.$APGECALL | — | $18.7M | 222,500 |
| BRIDGEBIO PHARMA INC | — | $18.6M | 250,000 |
| Viking Therapeutics, Inc.$VKTX | — | $17.1M | 525,181 |
| UNITED THERAPEUTICS Corp$UTHR | 80.1 | $16.2M | 27,303 |
 CYTOKINETICS INC$CYTKPUT | 28.0 | $13.2M | 200,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of DIADEMA PARTNERS LP's 144 positions.
Showing top 10 of 144 holdings.
Sector Allocation
Healthcare
$221.3M
Other
$18.6M
Technology
$2.3M
Full Holdings — DIADEMA PARTNERS LP (Q1 2026)
All 144 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $VRTXCALL | VERTEX PHARMACEUTICALS INC / MA | $41.6M | — | +5% | 76.6 |
| 2 | $LQDACALL | Liquidia Corp | $25.0M | — | NEW | 37.4 |
| 3 | $UTHRCALL | UNITED THERAPEUTICS Corp | $23.8M | — | NEW | 80.1 |
| 4 | $VKTXCALL | Viking Therapeutics, Inc. | $21.5M | — | -4% | — |
| 5 | $CAPRPUT | CAPRICOR THERAPEUTICS, INC. | $19.0M | — | +212% | — |
| 6 | $APGECALL | Apogee Therapeutics, Inc. | $18.7M | — | +5% | — |
| 7 | — | BRIDGEBIO PHARMA INC | $18.6M | 7.7% | +257% | — |
| 8 | $VKTX | Viking Therapeutics, Inc. | $17.1M | 7.1% | +56% | — |
| 9 | $UTHR | UNITED THERAPEUTICS Corp | $16.2M | 6.7% | +173% | 80.1 |
| 10 | $CYTKPUT | CYTOKINETICS INC | $13.2M | — | NEW | 28 |
| 11 |  $JNJ | JOHNSON & JOHNSON | $13.1M | 5.4% | -19% | 72.8 |
| 12 |  $COGT | Cogent Biosciences, Inc. | $12.4M | 5.1% | +145% | — |
| 13 |  $RVMDPUT | Revolution Medicines, Inc. | $12.2M | — | NEW | — |
| 14 |  $MRKPUT | Merck & Co., Inc. | $12.0M | — | NEW | 70.9 |
| 15 | $UTHRPUT | UNITED THERAPEUTICS Corp | $11.9M | — | NEW | 80.1 |
| 16 |  $ABVXCALL | Abivax S.A. | $11.1M | — | NEW | — |
| 17 | $ABVXPUT | Abivax S.A. | $11.1M | — | NEW | — |
| 18 |  $JAZZ | Jazz Pharmaceuticals plc | $10.4M | 4.3% | NEW | — |
| 19 | $CAPRCALL | CAPRICOR THERAPEUTICS, INC. | $10.0M | — | +5% | — |
| 20 |  $INCYPUT | INCYTE CORP | $9.9M | — | +5% | 81.2 |
| 21 |  $TERN | Terns Pharmaceuticals, Inc. | $9.6M | 4.0% | -47% | — |
| 22 |  $KODPUT | Kodiak Sciences Inc. | $9.4M | — | NEW | — |
| 23 |  $ROIVPUT | Roivant Sciences Ltd. | $9.3M | — | +5% | — |
| 24 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $8.4M | 3.5% | +1% | 74.1 |
| 25 | $ABVX | Abivax S.A. | $8.2M | 3.4% | +0% | — |
| 26 |  $MRNAPUT | Moderna, Inc. | $8.1M | — | NEW | 15.9 |
| 27 | $RVMD | Revolution Medicines, Inc. | $7.9M | 3.3% | +118% | — |
| 28 | $KOD | Kodiak Sciences Inc. | $7.4M | 3.0% | NEW | — |
| 29 | $INCY | INCYTE CORP | $7.3M | 3.0% | NEW | 81.2 |
| 30 |  $TGTX | TG THERAPEUTICS, INC. | $6.9M | 2.8% | +68% | 68.4 |
| 31 |  $EWTXCALL | Edgewise Therapeutics, Inc. | $6.7M | — | NEW | — |
| 32 |  $CORTCALL | CORCEPT THERAPEUTICS INC | $6.4M | — | NEW | 55.4 |
| 33 |  $BBIO | BridgeBio Pharma, Inc. | $6.3M | 2.6% | +22% | 31.7 |
| 34 |  $GPCRPUT | Structure Therapeutics Inc. | $6.1M | — | NEW | — |
| 35 |  $IMCR | Immunocore Holdings plc | $5.8M | 2.4% | +175% | — |
| 36 |  $LLY | ELI LILLY & Co | $5.5M | 2.3% | +200% | 89.3 |
| 37 |  $ABBV | AbbVie Inc. | $5.2M | 2.2% | NEW | 59.3 |
| 38 |  $RCUS | Arcus Biosciences, Inc. | $5.1M | 2.1% | NEW | 12 |
| 39 |  $CRSPCALL | CRISPR Therapeutics AG | $5.1M | — | -6% | 4.5 |
| 40 |  $QUREPUT | uniQure N.V. | $4.9M | — | -1% | — |
| 41 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $4.1M | 1.7% | NEW | — |
| 42 | $QURECALL | uniQure N.V. | $4.1M | — | NEW | — |
| 43 |  $CRVS | Corvus Pharmaceuticals, Inc. | $3.6M | 1.5% | NEW | — |
| 44 |  $ZYME | Zymeworks Inc. | $3.6M | 1.5% | NEW | 27.2 |
| 45 |  $REPLPUT | Replimune Group, Inc. | $3.5M | — | NEW | — |
| 46 | $GPCR | Structure Therapeutics Inc. | $3.5M | 1.4% | NEW | — |
| 47 | $CYTKCALL | CYTOKINETICS INC | $3.3M | — | NEW | 28 |
| 48 |  $PCVXCALL | Vaxcyte, Inc. | $3.1M | — | NEW | — |
| 49 |  $GLUE | Monte Rosa Therapeutics, Inc. | $3.1M | 1.3% | +201% | 18.1 |
| 50 |  $TENX | TENAX THERAPEUTICS, INC. | $2.9M | 1.2% | -26% | — |
| 51 |  $BHVNCALL | Biohaven Ltd. | $2.7M | — | +59% | — |
| 52 |  $HRMY | Harmony Biosciences Holdings, Inc. | $2.6M | 1.1% | +1138% | 75.3 |
| 53 |  $NTLACALL | Intellia Therapeutics, Inc. | $2.6M | — | -6% | 24.5 |
| 54 | $CAPR | CAPRICOR THERAPEUTICS, INC. | $2.4M | 1.0% | -50% | — |
| 55 |  $EYPT | EyePoint, Inc. | $2.3M | 0.9% | NEW | 10.3 |
| 56 |  $BCYC | BICYCLE THERAPEUTICS PLC | $2.2M | 0.9% | NEW | — |
| 57 |  $ALMSCALL | ALUMIS INC. | $2.2M | — | NEW | 9.2 |
| 58 |  $INDV | Indivior Pharmaceuticals, Inc. | $2.2M | 0.9% | +312% | 64.6 |
| 59 |  $NVOPUT | NOVO NORDISK A S | $2.1M | — | +5% | — |
| 60 |  $CELCCALL | Celcuity Inc. | $2.0M | — | NEW | — |
| 61 |  $CLYM | Climb Bio, Inc. | $2.0M | 0.8% | NEW | — |
| 62 |  $ANNXCALL | Annexon, Inc. | $2.0M | — | +14% | — |
| 63 |  $IVA | Inventiva S.A. | $1.9M | 0.8% | +5% | — |
| 64 |  $STTK | Shattuck Labs, Inc. | $1.9M | 0.8% | NEW | — |
| 65 | $LQDAPUT | Liquidia Corp | $1.9M | — | NEW | 37.4 |
| 66 |  $TARS | Tarsus Pharmaceuticals, Inc. | $1.8M | 0.8% | NEW | 40.8 |
| 67 |  $ALKS | Alkermes plc. | $1.8M | 0.7% | NEW | — |
| 68 |  $MGNX | MACROGENICS INC | $1.7M | 0.7% | NEW | 31.7 |
| 69 | $VRTX | VERTEX PHARMACEUTICALS INC / MA | $1.7M | 0.7% | -62% | 76.6 |
| 70 |  $VYGR | Voyager Therapeutics, Inc. | $1.6M | 0.7% | NEW | 5.5 |
| 71 | $REPLCALL | Replimune Group, Inc. | $1.6M | — | NEW | — |
| 72 | $CRVSCALL | Corvus Pharmaceuticals, Inc. | $1.6M | — | NEW | — |
| 73 |  $CTMXCALL | CytomX Therapeutics, Inc. | $1.5M | — | NEW | 19.1 |
| 74 |  $AVXLCALL | ANAVEX LIFE SCIENCES CORP. | $1.5M | — | +240% | — |
| 75 | $PCVX | Vaxcyte, Inc. | $1.5M | 0.6% | +9% | — |
| 76 |  $RLMD | RELMADA THERAPEUTICS, INC. | $1.4M | 0.6% | -48% | — |
| 77 | $EYPTCALL | EyePoint, Inc. | $1.4M | — | NEW | 10.3 |
| 78 |  $KPTICALL | Karyopharm Therapeutics Inc. | $1.3M | — | NEW | 20.4 |
| 79 |  $SLSCALL | SELLAS Life Sciences Group, Inc. | $1.3M | — | -29% | — |
| 80 |  $OLMACALL | Olema Pharmaceuticals, Inc. | $1.3M | — | -13% | — |
| 81 |  $CRMDPUT | CorMedix Inc. | $1.1M | — | +5% | 75.5 |
| 82 | $CRBPCALL | Corbus Pharmaceuticals Holdings, Inc. | $1.1M | — | NEW | — |
| 83 |  $IOVACALL | IOVANCE BIOTHERAPEUTICS, INC. | $1.1M | — | NEW | 30.6 |
| 84 |  $BIOA | BioAge Labs, Inc. | $1.0M | 0.4% | -78% | 28.6 |
| 85 |  $INO | INOVIO PHARMACEUTICALS, INC. | $979,037 | 0.4% | +5% | — |
| 86 |  $AYTU | AYTU BIOPHARMA, INC | $963,900 | 0.4% | +15% | 21.5 |
| 87 |  $EQ | Equillium, Inc. | $867,688 | 0.4% | +25% | 27.2 |
| 88 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $839,200 | 0.3% | NEW | 26.8 |
| 89 |  $PHVS | Pharvaris N.V. | $828,318 | 0.3% | NEW | — |
| 90 |  $ENTA | ENANTA PHARMACEUTICALS INC | $820,344 | 0.3% | -0% | 15.5 |
| 91 |  $IBRXPUT | ImmunityBio, Inc. | $815,321 | — | NEW | 30 |
| 92 |  $VIRCALL | Vir Biotechnology, Inc. | $795,648 | — | -0% | 5.6 |
| 93 | $REPL | Replimune Group, Inc. | $770,049 | 0.3% | -56% | — |
| 94 |  $XERS | Xeris Biopharma Holdings, Inc. | $769,927 | 0.3% | -22% | 45.5 |
| 95 |  $LRMR | Larimar Therapeutics, Inc. | $749,867 | 0.3% | NEW | — |
| 96 | $ANNX | Annexon, Inc. | $736,355 | 0.3% | -62% | — |
| 97 |  $RARE | Ultragenyx Pharmaceutical Inc. | $736,267 | 0.3% | NEW | 31 |
| 98 |  $MLYS | Mineralys Therapeutics, Inc. | $713,740 | 0.3% | +5% | — |
| 99 |  $UNCY | Unicycive Therapeutics, Inc. | $698,026 | 0.3% | NEW | — |
| 100 | $ALMSPUT | ALUMIS INC. | $687,336 | — | NEW | 9.2 |
| 101 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $653,500 | 0.3% | NEW | — |
| 102 |  $PHAT | Phathom Pharmaceuticals, Inc. | $607,162 | 0.3% | NEW | 32.5 |
| 103 | $CELC | Celcuity Inc. | $606,540 | 0.3% | NEW | — |
| 104 | $VYGRCALL | Voyager Therapeutics, Inc. | $579,000 | — | NEW | 5.5 |
| 105 |  $OCGNCALL | Ocugen, Inc. | $543,000 | — | NEW | — |
| 106 |  $CNTB | Connect Biopharma Holdings Ltd | $525,808 | 0.2% | NEW | — |
| 107 | $NVO | NOVO NORDISK A S | $520,736 | 0.2% | NEW | — |
| 108 |  $PTHS | Pelthos Therapeutics Inc. | $520,481 | 0.2% | -1% | 25.4 |
| 109 |  $EOLSCALL | Evolus, Inc. | $514,572 | — | +5% | 30 |
| 110 | $QURE | uniQure N.V. | $510,120 | 0.2% | -31% | — |
| 111 |  $MNKD | MANNKIND CORP | $457,177 | 0.2% | -38% | 44.4 |
| 112 |  $MAZE | Maze Therapeutics, Inc. | $447,750 | 0.2% | NEW | 19.7 |
| 113 |  $JANXCALL | Janux Therapeutics, Inc. | $439,240 | — | +5% | 24.8 |
| 114 |  $URGN | UroGen Pharma Ltd. | $416,327 | 0.2% | +6% | — |
| 115 | $CORT | CORCEPT THERAPEUTICS INC | $403,100 | 0.2% | -90% | 55.4 |
| 116 |  $LPCN | Lipocine Inc. | $399,500 | 0.2% | -81% | — |
| 117 |  $FHTX | Foghorn Therapeutics Inc. | $382,132 | 0.2% | +161% | 11.2 |
| 118 |  $GHRS | GH Research PLC | $377,314 | 0.2% | NEW | — |
| 119 | $OCGN | Ocugen, Inc. | $362,000 | 0.1% | NEW | — |
| 120 |  $PRQR | ProQR Therapeutics N.V. | $291,734 | 0.1% | +7% | — |
| 121 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $289,600 | 0.1% | NEW | — |
| 122 |  $PEPG | PepGen Inc. | $267,137 | 0.1% | NEW | — |
| 123 |  $TRVI | Trevi Therapeutics, Inc. | $258,440 | 0.1% | -78% | — |
| 124 |  $PGEN | PRECIGEN, INC. | $213,984 | 0.1% | NEW | 38.6 |
| 125 |  $UPB | Upstream Bio, Inc. | $194,481 | 0.1% | +5% | 22.6 |
| 126 |  $CMPS | COMPASS Pathways plc | $176,324 | 0.1% | NEW | — |
| 127 |  $PASG | Passage BIO, Inc. | $153,311 | 0.1% | NEW | — |
| 128 | $INOCALL | INOVIO PHARMACEUTICALS, INC. | $130,848 | — | -25% | — |
| 129 |  $TLPH | TALPHERA, INC. | $114,696 | 0.1% | +12% | — |
| 130 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $109,473 | 0.1% | NEW | — |
| 131 |  $MNPR | Monopar Therapeutics | $89,308 | 0.0% | NEW | — |
| 132 |  $LYELPUT | Lyell Immunopharma, Inc. | $82,246 | — | +8% | 3.6 |
| 133 |  $VTGN | Vistagen Therapeutics, Inc. | $60,252 | 0.0% | +5% | — |
| 134 |  $RNA | Avidity Biosciences, Inc. | $33,585 | 0.0% | NEW | 22.3 |
| 135 |  $CUE | Cue Biopharma, Inc. | $30,346 | 0.0% | NEW | 23.2 |
| 136 |  $ENTX | Entera Bio Ltd. | $25,819 | 0.0% | NEW | — |
| 137 |  $PRTC | PureTech Health plc | $11,327 | 0.0% | +6% | — |
| 138 | $IOVAPUT | IOVANCE BIOTHERAPEUTICS, INC. | $10,179 | — | NEW | 30.6 |
| 139 |  $ATYRPUT | aTYR PHARMA INC | $9,750 | — | +6% | — |
| 140 |  $ELVN | Enliven Therapeutics, Inc. | $9,604 | 0.0% | NEW | — |
| 141 | $ATYRCALL | aTYR PHARMA INC | $9,516 | — | -21% | — |
| 142 | $KODCALL | Kodiak Sciences Inc. | $7,624 | — | -99% | — |
| 143 |  $SEPN | Septerna, Inc. | $4,854 | 0.0% | NEW | 44.6 |
| 144 |  $JBIOPUT | Jade Biosciences, Inc. | $2,930 | — | +0% | — |
New Positions (74)
$LQDACALL Liquidia Corp$25.0M$UTHRCALL UNITED THERAPEUTICS Corp$23.8M$CYTKPUT CYTOKINETICS INC$13.2M$RVMDPUT Revolution Medicines, Inc.$12.2M$MRKPUT Merck & Co., Inc.$12.0M$UTHRPUT UNITED THERAPEUTICS Corp$11.9M$ABVXCALL Abivax S.A.$11.1M$ABVXPUT Abivax S.A.$11.1M$JAZZ Jazz Pharmaceuticals plc$10.4M$KODPUT Kodiak Sciences Inc.$9.4M$MRNAPUT Moderna, Inc.$8.1M$KOD Kodiak Sciences Inc.$7.4M$INCY INCYTE CORP$7.3M$EWTXCALL Edgewise Therapeutics, Inc.$6.7M$CORTCALL CORCEPT THERAPEUTICS INC$6.4MExited Positions (76)
$PRAXPUT Praxis Precision Medicines, Inc.$RNACALL Avidity Biosciences, Inc.
$QQQPUT INVESCO QQQ TRUST, SERIES 1$JAZZCALL Jazz Pharmaceuticals plc$BBIOPUT BridgeBio Pharma, Inc.$GPCRCALL Structure Therapeutics Inc.$VKTXPUT Viking Therapeutics, Inc.$BBIOCALL BridgeBio Pharma, Inc.$JNJCALL JOHNSON & JOHNSON
$INSMCALL INSMED Inc
$IONSCALL IONIS PHARMACEUTICALS INC
$REGN REGENERON PHARMACEUTICALS, INC.$INDVCALL Indivior Pharmaceuticals, Inc.
$OCULCALL OCULAR THERAPEUTIX, INCBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for DIADEMA PARTNERS LP including:
Track DIADEMA PARTNERS LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for DIADEMA PARTNERS LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: DIADEMA PARTNERS LP
13F Pro is an AI hedge fund tracker and stock research platform. For DIADEMA PARTNERS LP (SEC CIK: 2026172), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in DIADEMA PARTNERS LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.